CORT beat EPS expectations by 53.00%
Feb 24, 2026, 11:34 PM
0.00%
What does CORT do
Corcept Therapeutics, based in Menlo Park, California, is a commercial-stage pharmaceutical company that markets Korlym for Cushing's syndrome and has a portfolio of selective cortisol modulators. Founded in 2004, it employs 352 people and offers around 1,000 compounds.
Corcept Therapeutics (CORT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Corcept Therapeutics's actual EPS was $0.20, beating the estimate of $0.31 per share, resulting in a 53.00% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.